News-Medical.Net on MSN
Durvalumab extends survival in small cell lung cancer but raises cost concerns
A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living ...
The anti-cancer drug durvalumab used in immunotherapy delivers a 66-month survival breakthrough for lung cancer patients, ...
Wendy Brooks, a survivor of extensive-stage small cell lung cancer, and her husband and care partner, Larry Brooks, spoke ...
Stocktwits on MSN
IBRX garners retail attention on positive update in immunotherapy for lung cancer patients
The company said that responding patients lived longer overall, with a median survival of 16.2 months. ・The data come from ...
Lung cancer patients receiving immunochemotherapy earlier in the day had a 52% lower risk of progression in a new medical study.
A 69-year-old Greeley woman had just hiked 8 miles in Sedona, Arizona, when she received a call that she had lung cancer. Despite her active lifestyle, a past of smoking crept up on her without any ...
Medicaid expansion under the ACA improved long-term survival for younger adults with operable lung cancer, despite no earlier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback